Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

BI-3406, a Potent and Selective SOS1–KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition
Marco H. Hofmann, Michael Gmachl, Jürgen Ramharter, et al.
Cancer Discovery (2020) Vol. 11, Iss. 1, pp. 142-157
Open Access | Times Cited: 329

Showing 26-50 of 329 citing articles:

The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives
Mitsunobu Takeda, Shoma Yoshida, Takuya Inoue, et al.
Cancers (2025) Vol. 17, Iss. 3, pp. 428-428
Open Access | Times Cited: 4
Targeting KRAS: from metabolic regulation to cancer treatment
Yanyan Shi, Huiling Zheng, Tianzhen Wang, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 3
The roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy
Qinglong Ma, Wenyang Zhang, Kongming Wu, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 3
The biological underpinnings of therapeutic resistance in pancreatic cancer
Gregory L. Beatty, Gregor Werba, Costas A. Lyssiotis, et al.
Genes & Development (2021) Vol. 35, Iss. 13-14, pp. 940-962
Open Access | Times Cited: 86
Targeting Son of Sevenless 1: The pacemaker of KRAS
Dirk Kessler, Daniel Gerlach, Norbert Kraut, et al.
Current Opinion in Chemical Biology (2021) Vol. 62, pp. 109-118
Open Access | Times Cited: 74
KRAS Inhibitor Resistance in MET-Amplified KRASG12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms
Shinichiro Suzuki, Kimio Yonesaka, Takeshi Teramura, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 20, pp. 5697-5707
Open Access | Times Cited: 74
Targeting KRAS in pancreatic cancer: new drugs on the horizon
Sahar F. Bannoura, Md. Hafiz Uddin, Misako Nagasaka, et al.
Cancer and Metastasis Reviews (2021) Vol. 40, Iss. 3, pp. 819-835
Open Access | Times Cited: 71
The G protein signaling regulator RGS3 enhances the GTPase activity of KRAS
Chuanchuan Li, Alberto Vides, Dong-Sung Kim, et al.
Science (2021) Vol. 374, Iss. 6564, pp. 197-201
Open Access | Times Cited: 71
SOS GEFs in health and disease
Fernando C. Baltanás, Natasha Zarich, José M. Rojas, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2020) Vol. 1874, Iss. 2, pp. 188445-188445
Open Access | Times Cited: 70
Drugging the Undruggable: Advances on RAS Targeting in Cancer
Mı́riam Molina-Arcas, Amit Samani, Julian Downward
Genes (2021) Vol. 12, Iss. 6, pp. 899-899
Open Access | Times Cited: 68
The ERK mitogen-activated protein kinase signaling network: the final frontier in RAS signal transduction
Jennifer E. Klomp, Jeffrey A. Klomp, Channing J. Der
Biochemical Society Transactions (2021) Vol. 49, Iss. 1, pp. 253-267
Closed Access | Times Cited: 63
Targeting KRAS in Cancer: Promising Therapeutic Strategies
Lisa Maria Mustachio, Anca Chelariu-Raicu, Lóránt Székvölgyi, et al.
Cancers (2021) Vol. 13, Iss. 6, pp. 1204-1204
Open Access | Times Cited: 63
Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein–Protein Interaction
John M. Ketcham, Jacob R. Haling, Shilpi Khare, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 14, pp. 9678-9690
Open Access | Times Cited: 63
Targeting KRAS: The Elephant in the Room of Epithelial Cancers
Valeria Merz, Marina Gaule, Camilla Zecchetto, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 61
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
Daolin Tang, Guido Kroemer, Rui Kang
Molecular Cancer (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 61
Oncogenic KRAS: Signaling and Drug Resistance
Hyeon Jin Kim, Han Na Lee, Mi Suk Jeong, et al.
Cancers (2021) Vol. 13, Iss. 22, pp. 5599-5599
Open Access | Times Cited: 56
Discovery of the First-in-Class Agonist-Based SOS1 PROTACs Effective in Human Cancer Cells Harboring Various KRAS Mutations
Chuan Zhou, Zisheng Fan, Zehui Zhou, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 5, pp. 3923-3942
Closed Access | Times Cited: 56
Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRASG12C Inhibitor
Joachim Bröker, Alex G. Waterson, Chris A. Smethurst, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 21, pp. 14614-14629
Open Access | Times Cited: 51
Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
Anne-Laure Désage, Camille Léonce, Aurélie Swalduz, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 47
Highly Potent, Selective, Biostable, and Cell-Permeable Cyclic d-Peptide for Dual-Targeting Therapy of Lung Cancer
Yunjiang Zhou, Yunting Zou, Mei Yang, et al.
Journal of the American Chemical Society (2022) Vol. 144, Iss. 16, pp. 7117-7128
Closed Access | Times Cited: 40
KRAS mutant–driven SUMOylation controls extracellular vesicle transmission to trigger lymphangiogenesis in pancreatic cancer
Yuming Luo, Zhihua Li, Yao Kong, et al.
Journal of Clinical Investigation (2022) Vol. 132, Iss. 14
Open Access | Times Cited: 39
Interrogation of cancer gene dependencies reveals paralog interactions of autosome and sex chromosome-encoded genes
Anna Köferle, Andreas Schlattl, Alexandra Hörmann, et al.
Cell Reports (2022) Vol. 39, Iss. 2, pp. 110636-110636
Open Access | Times Cited: 38
Discovery of Potential KRAS‐SOS1 Inhibitors from South African Natural Compounds: An In silico Approach
Abdul Rashid Issahaku, Elliasu Y. Salifu, Clement Agoni, et al.
ChemistrySelect (2023) Vol. 8, Iss. 24
Closed Access | Times Cited: 34
KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression
Zining Zhang, Heng Zhang, Xiang Liao, et al.
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access | Times Cited: 28
Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS
Guowei Yin, Jing Huang, Johnny Petela, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 27

Scroll to top